Retail price list of ensifentrine-Ohtuvayre in domestic pharmacies

Ensifentrine Inhalation Suspension Solution (Ensifentrine)-OhtuvayreThe original drug has not yet been officially launched in China, but there is news of limited supply in some administrative regions, and the specific retail price and medical insurance coverage are still unclear. According to overseas market information, the specifications of the US version of the original drug are 3mg/2.5mL (60 doses), and each box is priced at more than 40,000 yuan. The price may fluctuate to a certain extent due to factors such as exchange rates and procurement channels. It is worth noting that there are currently no generic drugs on the market in China, so patients who need to use them can only obtain them through overseas channels or pharmacies in the special zone, which has obvious limitations in terms of cost and convenience of medication.

Due to high drug prices and limited access, doctors in clinical practice usually advise patients to comprehensively consider the severity of their condition, their affordability, and alternative treatment options. Short-term or auxiliary use of exefantine may be suitable for patients with significant symptom fluctuations or poor response to traditional inhaled drugs, but the economic burden and drug sustainability need to be assessed before long-term use. At the same time, patients must follow professional medical guidance when obtaining drugs and avoid purchasing through informal channels to ensure drug quality, safety and reliable efficacy.

In the future, with the global clinical application promotion and potential marketing approval of exefantine, its domestic accessibility is expected to gradually increase. Once it is formally approved, it is expected that prices and medical insurance policies will gradually become clear, which will help reduce the financial burden on patients and expand the scope of the treatable population. Overall, exefantine, as an innovative dual-mechanism inhaled drug, has certain potential in the management of chronic obstructive pulmonary disease. However, its high cost and the fact that it is not yet on the market are still major constraints in clinical application. When using it, patients should comprehensively evaluate the efficacy, safety and feasibility under the guidance of a doctor, and formulate a treatment plan to achieve the best results in the management of chronic obstructive pulmonary disease (COPD).

Reference materials:https://www.drugs.com/monograph/ensifentrine.html